Aqua Bio Technology — Share Issue/Capital Change 2024

Jun 28, 2024

Aqua Bio Technology ASA: Cosmed and Ovalen AS settlement

Aqua Bio Technology ASA: Cosmed and Ovalen AS settlement

28.6.2024 14:46:59 CEST | Aqua Bio Technology ASA | Total number of voting

rights and capital

Reference is made to the stock exchange announcements made by Aqua Bio

Technology ASA ("ABT" or the "Company") on 12 April and 23 April 2024,

respectively, regarding the completion of ABT's acquisition of Ovalen AS and the

settlement of the earn-out in relation to the Company's acquisition of Cosmed

Beauty AS and Ultrabody AB (jointly, "Cosmed").

The Company's board of directors has resolved to issue 1,200,000 consideration

shares at a subscription price of NOK 5 per consideration share to the previous

owner of Ovalen AS. Moreover, for accounting purposes, the buy-out owed to

Varming Holding AS in connection with the Company's acquisition of Cosmed has

been rescinded, and the settlement of the buy-out has been agreed to be amended.

On this basis, the Company's board of directors has resolved to issue 4,707,935

shares at a subscription price of NOK 4 to Varming Holding AS, with the share

deposit being settled by way of set-off.

****

For further information, please contact CEO Håvard Lindstrøm mobile phone +47

941 32 288.

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skincare products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skincare products developed by partners towards consumers and

professional users. ABT's focus on commercialization and development of natural

ingredients and natural skincare products has been, and will continue to be, an

important part of the Company's strategy going forward. Aqua Bio Technology is

listed on the Euronext Expand market of the Oslo Stock Exchange.

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation and subject to the disclosure requirements pursuant to

section 5-12 of the Norwegian Securities Trading Act. This stock exchange notice

was published by CEO Håvard Lindstrøm on the date and time provided.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section

of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Håvard Lindstrøm, 004794132288, hl@aquabiotech.no

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable

biotechnology for use in skin care products. ABT's cosmetics ingredients are

highly effective and they provide the cosmetics industry with natural

alternatives to traditional ingredients. ABT is also marketing and distributing

natural skin care products developed by partners towards consumers and

professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -

https://kommunikasjon.ntb.no/ir-files/17847556/18165345/4724/Download%20announce

ment%20as%20PDF.pdf